Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update

International Journal of Cancer

Volumn 118, Issue 9, 2006, Pages 2281-2284

  Gronwald, Jacek ^a   Tung, Nadine ^b   Foulkes, William D ^c   Offit, Kenneth ^d   Gershoni, Ruth ^e   Daly, Mary ^f   Kim Sing, Charmaine ^g   Olsson, Hakan ^h   Ainsworth, Peter ⁱ   Eisen, Andrea ^j   Saal, Howard ^k   Friedman, Eitan ^l   Olopade, Olufunmilayo ^m   Osborne, Michael ⁿ   Weitzel, Jeffrey ^o   Lynch, Henry ^p   Ghadirian, Parviz ^q   Lubinski, Jan ^a   Sun, Ping ^r   Narod, Steven A ^r   Gilchrist, D ^s   Weber, B ^t   Rebbeck, T ^t   Isaacs, C ^u   Neuhausen, S ^v   Garber, J ^w   Karlan, B ^x   Fishman, D ^y   Merajver, S ^z   McKinnon, W ^aa   Wood, M ^aa   Evans, G ^ab   Moller, P ^ac   Pasini, B ^ad   Sweet, K ^ae   Eng, C ^ae   Rennert, G ^af   Couch, F ^ag   McLennan, J ^ah   Provencher, D ^q   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e RAMBAM MEDICAL CENTER   (Israel)

^f FOX CHASE CANCER CENTER   (United States)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ LONDON HEALTH SCIENCES CENTRE   (Canada)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l SHEBA MEDICAL CENTER   (Israel)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ Strang Cancer Prevention Centre   (United States)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITÉ DE MONTRÉAL   (Canada)

^r UNIVERSITY OF TORONTO   (Canada)

^s UNIVERSITY OF ALBERTA   (Canada)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u GEORGETOWN UNIVERSITY   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w DANA FARBER CANCER INSTITUTE   (United States)

^x CEDARS SINAI MEDICAL CENTER   (United States)

^y NORTHWESTERN UNIVERSITY   (United States)

^z UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^aa UNIVERSITY OF VERMONT   (United States)

^ab ST MARY S HOSPITAL   (United Kingdom)

^ac OSLO UNIVERSITY HOSPITAL   (Norway)

^ad UNIVERSITY OF GENOA   (Italy)

^ae OHIO UNIVERSITY   (United States)

^af TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^ag MAYO CLINIC   (United States)

^ah UNIVERSITY OF SAN FRANCISCO   (United States)

more..

Author keywords

BRCA1; BRCA2; Breast cancer; Oophorectomy; Tamoxifen

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ADULT; BRCA2 GENE; BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DRUG USE; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; ONCOGENE; OVARIECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SECOND CANCER; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; FUNCTIONAL LATERALITY; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PEDIGREE; PREMENOPAUSE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TAMOXIFEN;

EID: 33645675556     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21536     Document Type: Review

References (17)

1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
2. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.
3. Narod SA, Brunei JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, et al., Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2000;356:1876-81.
4. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC. Wagner A, van den Ouweland A, Devilee P, Meijers-Heijboer EJ, et al. Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 1998;251:316-21.
5. Robson M, Gilewski T, Haas B. Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K. BRCA-associated breast cancer in young women. J Clin Oncol 1998;16:1642-9.
6. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status in breast cancers in Ashkenazi Jewish women. Cancer 1997;80:435-41.
7. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
8. Loman N, Johannsson O, Bendahl P-O, Borg A, Ferno M, Olsson AH. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-19.
9. Eisinger F, Jacquemier J, Nogues C, Birnbaum D, Sobol H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptiblity genes. Cancer 1999;85:2291-5.
10. Lahkani SR, Easton DFD, Siratton MR, Storfer-Isser A, Anderson TJ, Farid LM, Gusterson BA, Jaquemier J, Sloane JP, Venter D, Van de Vijver MJ, Bishop DT, et al. Pathology of familial breast cancer; differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
11. Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, et al. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 2005;14:1534-8.
12. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-23.
13. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
14. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
15. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber BL, Rebbeck TR, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, et al. Oophorectomy and breast cancer in BRCA carriers. J Clin Oncol, in press.
16. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-60.
17. Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005;96:222-6.